theMednet - Have you begun to incorporate high dose IV iron infusions into your practice for patients newly started on hemodialysis with TSAT < 30% and ferritin < 400 to reduce risk for non-fatal CV events based on findings from the PIVOTAL trial?

Community
Company
News
Contact Us
Sign in

Topics: Cardiology • Preventive Cardiology

Have you begun to incorporate high dose IV iron infusions into your practice for patients newly started on hemodialysis with TSAT < 30% and ferritin < 400 to reduce risk for non-fatal CV events based on findings from the PIVOTAL trial?

Related Questions

Are there any ongoing clinical trials related to endothelial dysfunction and accelerated or premature CAD that patients might be able to enroll in nationwide?

What is your target or goal lipoprotein (a) level for patients on PCSK9 inhibitors for either primary or secondary prevention?

Is there a specific INR cut-off value that would prompt you to consider administering vitamin K for patients with mechanical valves requiring urgent non-cardiac surgery and if so, what would be your starting dose?

Given that there are a fair number of myocarditis cases without a troponin elevation, how do you clinically approach the diagnosis of myocarditis?

With the recent trials such as SELECT and STEP-HFpEF demonstrating benefits of GLP1-agonists in terms of CV risk reduction and improved exercise function, have you begun to incorporate this class of medications into routine CV health maintenance for patients with HFpEF and/or pre-existing CAD?

What is your approach to counseling an octogenarian on the risks and benefits of LHC in the context of NSTEMI complicated by new-onset heart failure and AKI on CKD?

For patients with hypertension who have normal filling pressures following right cardiac catheterization, can hypertension still be attributed to volume overload?

When would you consider adding an SGLT2 inhibitor, MRA, and/or ARNI (in lieu of ACE inhibitor or ARB) when discharging patients following revascularization for acute MI with newly reduced LV systolic function?

Is there a role of prophylactic aspirin in patients with incidental findings of aortic atherosclerosis but no history CAD or CVA?

How does the TACTiC trial's success with a web app for statin self-management influence your stance on nonprescription statins for primary prevention amidst statin underuse?